Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification

Rowan Kuiper, Martin van Vliet, Annemiek Broyl, Yvonne de Knegt, Bronno van der Holt, Laila el Jarari, George Mulligan, Walter Gregory, PhD, Gareth J Morgan, MD PhD, Hartmut Goldschmidt, MD, Uta Bertsch, MD, Henk Lokhorst, Mark van Duin, Erik van Beers, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3092.

https://doi.org/10.1182/blood.V122.21.3092.3092

Published: 2013

Journal Articles

A High-Risk Survival Classifier for Multiple Myeloma

Rowan Kuiper, BSc, Annemiek Broyl, MD, Yvonne de Knegt, BSc, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Bronno van der Holt, PhD, Laila el Jarari, MSc, George Mulligan, PhD, Gareth Morgan, MD, Walter M Gregory, PhD, Hartmut Goldschmidt, MD, Henk M. Lokhorst, MD, Mark van Duin, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 1800.

https://doi.org/10.1182/blood.V118.21.1800.1800

Published: 2011

Journal Articles

MicroRNA Profiling In Multiple Myeloma

Sophie Corthals, Su Ming Sun, Rowan Kuiper, Yvonne de Knegt, Annemiek Broyl, MD, Bronno van der Holt, H. Berna Beverloo, PhD, Justine K Peeters, Mark van Duin, PhD, Henk M Lokhorst, Sonja Zweegman, Mojca Jongen-Lavrencic, MD, PhD, P. Sonneveld

Blood (2010) 116 (21): 302.

https://doi.org/10.1182/blood.V116.21.302.302

Published: 2010

Journal Articles

Development of Bortezomib Induced Peripheral Neuropathy (BiPN) In Multiple Myeloma: Incidence and Molecular Characterization In Newly Diagnosed Patients Treated with Bortezomib

Annemiek Broyl, MD, Sophie Corthals, Joost L.M. Jongen, MD, PhD, Bronno van der Holt, PhD, Rowan Kuiper, Yvonne de Knegt, Laila el Jarari, Uta Bertsch, MD, PhD, Henk Lokhorst, MD, PhD, Brian GM Durie, MD, PhD, Hartmut Goldschmidt, MD, PhD, Pieter Sonneveld, MD, PhD

Blood (2010) 116 (21): 304.

https://doi.org/10.1182/blood.V116.21.304.304

Published: 2010

Journal Articles

Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial

Annemiek Broyl, MD, Rowan Kuiper, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Yvonne de Knegt, Bronno van der Holt, PhD, Laila el Jarari, Berna Beverloo, PhD, H. Lokhorst, Sonja Zweegman, George Mulligan, PhD, Hartmut Goldschmidt, Mark van Duin, PhD, Pieter Sonneveld

Blood (2010) 116 (21): 445.

https://doi.org/10.1182/blood.V116.21.445.445

Published: 2010

Journal Articles

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

Annemiek Broyl, Dirk Hose, Henk Lokhorst, Yvonne de Knegt, Justine Peeters, Anna Jauch, Uta Bertsch, Arjan Buijs, Marian Stevens-Kroef, H. Berna Beverloo, Edo Vellenga, Sonja Zweegman, Marie-Josée Kersten, Bronno van der Holt, Laila el Jarari, George Mulligan, Hartmut Goldschmidt, Mark van Duin, Pieter Sonneveld

Blood (2010) 116 (14): 2543–2553.

https://doi.org/10.1182/blood-2009-12-261032

Published: 2010

Includes: Supplemental data

Journal Articles

Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma.

Sophie L Corthals, Hartmut Goldschmidt, David C Johnson, Henk Lokhorst, Yvonne de Knegt, Sonja Zweegman, Bronno van der Holt, Dirk Hose, Marie Jose Kersten, Edo Vellenga, Brian G M Durie, Gareth J Morgan, Pieter Sonneveld

Blood (2009) 114 (22): 1790.

https://doi.org/10.1182/blood.V114.22.1790.1790

Published: 2009

Journal Articles

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma.

Sophie L Corthals, David C Johnson, Yvonne de Knegt, Hartmut Goldschmidt, Henk Lokhorst, Stéphane Minvielle, Florence Magrangeas, Jean-Luc Harousseau, Brian G M Durie, Brian G Van Ness, Gareth J Morgan, Pieter Sonneveld, Hervé Avet Loiseau

Blood (2009) 114 (22): 1794.

https://doi.org/10.1182/blood.V114.22.1794.1794

Published: 2009

Journal Articles

Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients.

Rowan Kuiper, Sophie L Corthals, Payman Hanifi-Moghaddam, Yvonne de Knegt, Henk Lokhorst, Hartmut Goldschmidt, Brian G M Durie, Brian G Van Ness, Gareth J Morgan, Mark van Duin, Herve Avet-Loiseau, Pieter Sonneveld

Blood (2009) 114 (22): 1800.

https://doi.org/10.1182/blood.V114.22.1800.1800

Published: 2009

Journal Articles

MicroRNAs Are Differentially Expressed Among Cytogenetic Subgroups in Multiple Myeloma.

Sophie L Corthals, Mojca Jongen-Lavrencic, Yvonne de Knegt, Hartmut Goldschmidt, Henk Lokhorst, Pieter Sonneveld

Blood (2009) 114 (22): 2833.

https://doi.org/10.1182/blood.V114.22.2833.2833

Published: 2009

Journal Articles

Expression of Cancer Testis Antigens as Potential Targets for Immunotherapy Is Retained Following Treatment in Multiple Myeloma.

Mark van Duin, Surinder S. Sahota, Yvonne de Knegt, Annemiek Broyl, Debora Joseph-Pietras, George Mulligan, Barb Bryant, Pieter Sonneveld

Blood (2008) 112 (11): 1722.

https://doi.org/10.1182/blood.V112.11.1722.1722

Published: 2008

Journal Articles

Gene Expression Profiles as Prognostic Factors in Patients with Multiple Myeloma Treated with Conventional Versus Novel Agents in Correlation with Outcome.

Annemiek Broyl, MD, Dirk Hose, MD, PhD, Yvonne de Knegt, Henk Lokhorst, MD, PhD, Hartmut Goldschmidt, MD, PhD, Mark van Duin, PhD, Pieter Sonneveld, MD, PhD

Blood (2007) 110 (11): 3173.

https://doi.org/10.1182/blood.V110.11.3173.3173

Published: 2007

Journal Articles

Melphalan Resistance in Multiple Myeloma Can Be Overcome by Proteasome Inhibition or Histone Deacetylation: Lack of Syngergism of the Combination.

Pieter Sonneveld, MD, Eric Kamst, MSc, Yvonne de Knegt, Naomi Klarenbeek, Martijn Schoester

Blood (2005) 106 (11): 3393.

https://doi.org/10.1182/blood.V106.11.3393.3393

Published: 2005

Journal Articles

Influence of Genetic Single Nucleotide Polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 Genes on Survival and Treatment Related Toxicity in Patients with Multiple Myeloma Treated in the HOVON 24 Trial.

Pieter Sonneveld, MD, Celine Schilthuizen, Henk Lokhorst, MD, Edo Vellenga, MD, Reinier Raymakers, MD, Yvonne de Knegt, Eric Kamst, MSc, Bronno van der Holt, MSc

Blood (2005) 106 (11): 505.

https://doi.org/10.1182/blood.V106.11.505.505

Published: 2005

NARROW

Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification

A High-Risk Survival Classifier for Multiple Myeloma

MicroRNA Profiling In Multiple Myeloma

Development of Bortezomib Induced Peripheral Neuropathy (BiPN) In Multiple Myeloma: Incidence and Molecular Characterization In Newly Diagnosed Patients Treated with Bortezomib

Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma.

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma.

Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients.

MicroRNAs Are Differentially Expressed Among Cytogenetic Subgroups in Multiple Myeloma.

Expression of Cancer Testis Antigens as Potential Targets for Immunotherapy Is Retained Following Treatment in Multiple Myeloma.

Gene Expression Profiles as Prognostic Factors in Patients with Multiple Myeloma Treated with Conventional Versus Novel Agents in Correlation with Outcome.

Melphalan Resistance in Multiple Myeloma Can Be Overcome by Proteasome Inhibition or Histone Deacetylation: Lack of Syngergism of the Combination.

Influence of Genetic Single Nucleotide Polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 Genes on Survival and Treatment Related Toxicity in Patients with Multiple Myeloma Treated in the HOVON 24 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only